NASDAQ:CUE - Cue Biopharma Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $9.19 0.00 (0.00 %) (As of 09/21/2018 04:00 PM ET)Previous Close$9.19Today's Range$9.1350 - $9.4252-Week Range$7.57 - $17.99Volume250,590 shsAverage Volume71,283 shsMarket Capitalization$185.02 millionP/E RatioN/ADividend YieldN/ABetaN/A Company ProfileDiscussionChartEarnings HistoryInsider TradesHeadlinesOptions ChainSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Cue Biopharma, Inc., a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers and autoimmune disorders. The company's lead drug candidate includes CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to human papilloma virus related cancers. Its biologics drug candidates also comprise CUE-100 series to improve various tumor specific T cells; and CUE-200 series to reinvigorate exhausted T cells. The company also offers MOD costimulatory optimization and discovery platform and viraTope T cell epitope discovery platform to develop novel biologics for addressing new indications in oncology and autoimmune disorders. Cue Biopharma, Inc. has a collaboration agreement with Merck & Co. for the research and development of its proprietary biologics that target autoimmune disease indications. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is based in Cambridge, Massachusetts. Receive CUE News and Ratings via Email Sign-up to receive the latest news and ratings for CUE and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:CUE CUSIPN/A Webwww.cuebiopharma.com Phone781-305-7777 Debt Debt-to-Equity RatioN/A Current Ratio16.64 Quick Ratio16.64 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book Value$3.17 per share Price / Book2.90 Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous Employees30 Outstanding Shares20,130,000Market Cap$185.02 million Cue Biopharma (NASDAQ:CUE) Frequently Asked Questions What is Cue Biopharma's stock symbol? Cue Biopharma trades on the NASDAQ under the ticker symbol "CUE." How were Cue Biopharma's earnings last quarter? Cue Biopharma Inc (NASDAQ:CUE) released its quarterly earnings data on Monday, May, 14th. The company reported ($0.37) EPS for the quarter. View Cue Biopharma's Earnings History. When is Cue Biopharma's next earnings date? Cue Biopharma is scheduled to release their next quarterly earnings announcement on Monday, November, 12th 2018. View Earnings Estimates for Cue Biopharma. Who are some of Cue Biopharma's key competitors? Some companies that are related to Cue Biopharma include Crinetics Pharmaceuticals (CRNX), Epizyme (EPZM), AMAG Pharmaceuticals (AMAG), Flexion Therapeutics (FLXN), CymaBay Therapeutics (CBAY), Insys Therapeutics (INSY), Dova Pharmaceuticals (DOVA), Abeona Therapeutics (ABEO), Urogen Pharma (URGN), Obseva (OBSV), Kura Oncology (KURA), Verastem (VSTM), ANI Pharmaceuticals (ANIP), Vectura Group (VEGPF) and Basilea Pharmaceutica (BPMUF). Who are Cue Biopharma's key executives? Cue Biopharma's management team includes the folowing people: Mr. Daniel R. Passeri M.Sc., MSc., J.D., CEO, Pres & Director (Age 57)Mr. Colin G. Sandercock J.D., M.Sc., Sr. VP, Gen. Counsel & Sec. (Age 61)Dr. Ronald D. Seidel III, Exec. VP and Head of R&D (Age 42)Dr. Rodolfo J. Chaparro, Exec. VP & Head of Immunology (Age 45)Dr. Steven C. Almo, Founder and Chairman of Scientific & Clinical Advisory Board (Age 57) Who are Cue Biopharma's major shareholders? Cue Biopharma's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.38%), Nantahala Capital Management LLC (2.10%), Northern Trust Corp (0.90%), Bank of New York Mellon Corp (0.22%), Bank of New York Mellon Corp (0.22%) and Schwab Charles Investment Management Inc. (0.16%). Company insiders that own Cue Biopharma stock include Daniel R Passeri and Kerri-Ann Millar. View Institutional Ownership Trends for Cue Biopharma. Which institutional investors are buying Cue Biopharma stock? CUE stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Nantahala Capital Management LLC, Northern Trust Corp, Bank of New York Mellon Corp, Bank of New York Mellon Corp, Wealthsource Partners LLC, Schwab Charles Investment Management Inc. and Rhumbline Advisers. Company insiders that have bought Cue Biopharma stock in the last two years include Daniel R Passeri and Kerri-Ann Millar. View Insider Buying and Selling for Cue Biopharma. How do I buy shares of Cue Biopharma? Shares of CUE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Cue Biopharma's stock price today? One share of CUE stock can currently be purchased for approximately $9.19. How big of a company is Cue Biopharma? Cue Biopharma has a market capitalization of $185.02 million. Cue Biopharma employs 30 workers across the globe. What is Cue Biopharma's official website? The official website for Cue Biopharma is http://www.cuebiopharma.com. How can I contact Cue Biopharma? Cue Biopharma's mailing address is 21 ERIE STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at 781-305-7777. MarketBeat Community Rating for Cue Biopharma (NASDAQ CUE)Community Ranking: 2.0 out of 5 ( )Outperform Votes: 37 (Vote Outperform)Underperform Votes: 55 (Vote Underperform)Total Votes: 92MarketBeat's community ratings are surveys of what our community members think about Cue Biopharma and other stocks. Vote "Outperform" if you believe CUE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CUE will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 9/22/2018 by MarketBeat.com StaffFeatured Article: How Do Tariffs Affect Trade Balances?